{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:59:19Z","timestamp":1790233159613,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00335","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T23:25:39Z","timestamp":1520378739000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients"],"prefix":"10.3389","volume":"9","author":[{"given":"Hua","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr Gene Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.4049\/jimmunol.1502672","article-title":"Prime-boost immunization eliminates metastatic colorectal cancer by producing high-avidity effector CD8+ T Cells","volume":"198","author":"Xiang","year":"2017","journal-title":"J Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci Transl Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1006\/viro.1996.0239","article-title":"A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier","volume":"219","author":"Xiang","year":"1996","journal-title":"Virology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1089\/aid.2008.0212","article-title":"Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults","volume":"25","author":"Harro","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1189\/jlb.1A0813-451RR","article-title":"The effect of adenovirus-specific antibodies on adenoviral vector\u2013induced, transgene product\u2013specific T cell responses","volume":"96","author":"Small","year":"2014","journal-title":"J Leukoc Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1089\/hgtb.2016.114","article-title":"Preclinical evaluation of a replication-deficient recombinant adenovirus serotype 5 vaccine expressing guanylate cyclase C and the PADRE T-helper epitope","volume":"27","author":"Snook","year":"2016","journal-title":"Hum Gene Ther Methods"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1128\/CVI.00173-07","article-title":"Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines","volume":"14","author":"Appaiahgari","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11603","DOI":"10.1128\/JVI.75.23.11603-11613.2001","article-title":"Replication-defective vector based on a chimpanzee adenovirus","volume":"75","author":"Farina","year":"2001","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.4049\/jimmunol.171.8.4287","article-title":"Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice","volume":"171","author":"Xiang","year":"2003","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1097\/QAD.0000000000001224","article-title":"Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140","volume":"30","author":"Emmer","year":"2016","journal-title":"AIDS"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/jmv.23546","article-title":"Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults","volume":"85","author":"Zhang","year":"2013","journal-title":"J Med Virol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"28262","DOI":"10.18632\/oncotarget.8596","article-title":"Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab","volume":"7","author":"Xing","year":"2016","journal-title":"Oncotarget"},{"key":"B15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/sj.mt.6300078","article-title":"A CD46-binding chimpanzee adenovirus vector as a vaccine carrier","volume":"15","author":"Tatsis","year":"2007","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1038\/mtna.2016.25","article-title":"Hemagglutinin-targeting artificial microRNAs expressed by adenovirus protect mice from different clades of H5N1 infection","volume":"19","author":"Tang","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"B17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/mt.2012.248","article-title":"Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus","volume":"21","author":"Zhou","year":"2013","journal-title":"Mol Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1016\/j.vaccine.2015.08.016","article-title":"Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for coxsackievirus A16 and enterovirus 71","volume":"33","author":"Zhang","year":"2015","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ymthe.2006.03.027","article-title":"A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus","volume":"14","author":"Zhou","year":"2006","journal-title":"Mol Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.4049\/jimmunol.171.12.6774","article-title":"Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers","volume":"171","author":"Pinto","year":"2003","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.4049\/jimmunol.1302029","article-title":"The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion","volume":"193","author":"Zhang","year":"2014","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00705-013-1828-y","article-title":"The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary epatocellular carcinoma in China","volume":"159","author":"Jian","year":"2014","journal-title":"Arch Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2010.07.043","article-title":"Neutralizing antibodies to human and simian adenoviruses in humans and new-world monkeys","volume":"407","author":"Ersching","year":"2010","journal-title":"Virology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/jmv.23325","article-title":"Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China","volume":"84","author":"Yu","year":"2012","journal-title":"J Med Virol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1385\/MB:18:1:63","article-title":"Construction of adenoviral vectors","volume":"18","author":"Davis","year":"2001","journal-title":"Mol Biotechnol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1016\/j.vaccine.2009.03.080","article-title":"Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy","volume":"27","author":"Dudareva","year":"2009","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector","volume":"18","author":"Kostense","year":"2004","journal-title":"AIDS"},{"key":"B30","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1128\/CDLI.11.2.351-357.2004","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8729","DOI":"10.1128\/JVI.77.16.8729-8735","article-title":"Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines","volume":"77","author":"Barouch","year":"2003","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1128\/JVI.77.13.7663-7668.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1086\/593313","article-title":"HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine","volume":"47","author":"Quirk","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00335\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T23:25:42Z","timestamp":1520378742000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00335\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2018.00335"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00335","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"article-number":"335"}}